KOAG LLC, a Minneapolis-based medical device firm engaged in the design of innovative, topical vascular closure systems, announced today it received FDA clearance for its Vascette® HP device.
Vascette® is a unique, topical closure pad incorporating a proprietary, plant-derived, surgical hemostatic foam. The Vascette® patent-pending technology supports rapid hemostasis (blood stoppage) after cardiac catheterization without direct compression over the arterial puncture site (arteriotomy).
KOAG will exhibit the Vascette® HP at the American College of Cardiology meeting in New Orleans, March 4-6, 2023. The Company anticipates a clinical introduction during Q1, 2023.
KOAG LLC is a privately held medical device organization headquartered in suburban Minneapolis, MN.